BioSyngen
PrivateLast Round
Early Funding
Oct 20, 2021
Total Funding Raised
$43.5M
Company Overview
BioSyngen is a biotechnology company that develops first-in-class cell therapies, including CAR-T, TCR-T, and TILs, to treat solid tumors and other cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioSyngen Comparables
Compare BioSyngen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TCRCure Biopharma | 87% | |
| Lion TCR | 84% | |
| SCG Cell Therapy | 84% |
BioSyngen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 20, 2021 |
BioSyngen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Science City (Guangzhou) Investment Group Co., Ltd. | Early Funding |
Recent news
Latest coverage and updates
- is_developingAug 27, 2026
Biosyngen Pte. Ltd. is developing international medical platform focused on immune cell therapy for solid tumours.
BioSyngen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access